Építés alatt – nem éles oldal
Belépés
Befejeződött3. fázis

Open Label Study in Adolescents and Children With Myotonic Disorders

A legfontosabb adatok

Ki végzi
Lupin Ltd.
Hol
Franciaország1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Befejeződött
Fázis
3. fázis
Résztvevők
12 fő vett részt
Kezdés
2021. szept. 3.
Befejezés
2024. aug. 8.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • Mexiletine
A regiszteradat frissítve
2024. november 25.

Ki vehet részt

Életkor
6 év – 18 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 18 feltétel megnézéseKevesebb

Ki vehet részt

  • Male or female patients aged ≥ 6 and < 18 years who are able to comply with the study requirements
  • A genetically confirmed diagnosis of NDM or DM (DM1or DM2)
  • Presence of clinical symptoms of myotonia (hand grip myotonia, myotonia in the leg muscles, any other myotonia symptoms)
  • No significant cardiac abnormalities as determined by a cardiologist's assessment of the ECG and echocardiogram performed within 3 months prior to enrolment in the study. (If not done within 3 months before trial, electrocardiogram (ECG) and echocardiogram assessments will be performed at screening)
  • No history of any significant liver disorder
  • Patients receiving mexiletine treatment agree to stop treatment at least 7 days prior to initiation of treatment with Namuscla
  • Patients receiving other antimyotonic treatment agree to stop treatment for at least 7 times the half-life of respective drug
  • Laboratory investigations for haematology, biochemistry, and urinalysis at screening are within the normal range, or showing no clinically relevant abnormal values, as judged by the Investigator
  • Female patients of childbearing potential must be using an acceptable form of birth control as determined by the Investigator (e.g., oral contraception, implantable, injectable/transdermal hormonal contraception, intrauterine device (IUD), barrier methods), tubal ligation or are practicing abstinence
  • Patients able to provide assent to study participation and a parent or legal guardian to sign the written informed consent prior to study entry

Ki nem vehet részt

  • Strong inducer or inhibitor of CYP2D6 or CYP1A2 within 7 days prior to study drug administration
  • Any concurrent illness, or medications which could affect the muscle function
  • Concurrent participation in any other clinical trial
  • Any other neurological or psychiatric condition that might affect the study assessments
  • Seizure disorder, diabetes mellitus requiring treatment by insulin
  • Any contra-indication to mexiletine as listed in the Namuscla Summary of Product Characteristics (SmPC):; Hypersensitivity to the active substance, or to any of the excipients; Hypersensitivity to any local anaesthetic; Ventricular tachyarrhythmia; Complete heart block (i.e., third-degree atrioventricular block) or any heart block susceptible to evolve to complete heart block (first-degree atrioventricular block with markedly prolonged PR interval (≥ 200 ms) and/or wide QRS complex (≥ 120 ms), second-degree atrioventricular block, bundle branch block, bifascicular and trifascicular block),; QT interval > 450ms; Myocardial infarction (acute or past), or abnormal Q-waves; Symptomatic coronary artery disease; Heart failure with ejection fraction <50%; Atrial tachyarrhythmia, fibrillation or flutter; Sinus node dysfunction (including sinus rate < 50 bpm); Co-administration with medicinal products inducing torsades de pointes (class Ia, Ic, III antiarrhythmics): Co-administration of mexiletine and antiarrhythmics inducing torsades de pointesclass Ia: quinidine, procainamide, disopyramide, ajmaline; class Ic: encainide, flecainide, propafenone, moricizine; class III: amiodarone, sotalol, ibutilide, dofetilide, dronedarone, vernakalant) increases the risk of potentially lethal torsades de pointes; Co-administration with medicinal products with narrow therapeutic index
  • Any clinically significant illness, laboratory findings, ECG, or other clinical symptoms, which in the opinion of the Investigator could affect the patient's optimal participation in the study
  • Pregnant or breastfeeding

Hol van ez a vizsgálat?

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

This is an open-label, multi-centre, single arm, interventional study to describe the steady-state PK, safety, and efficacy of mexiletine in paediatric patients (6 to <18 years of age) with myotonic disorders.

A vizsgálat csoportja

  • Cohort 1 and 2Egyéb csoport

    7 patients aged 12 to \< 18 years , inclusive in cohort-1 7 patients aged 6 to \< 12 years, inclusive in cohort-2

    Kezelés: Mexiletine

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
An Open-label, Non-Comparative Study to Evaluate the Steady-State Pharmacokinetics, Safety, and Efficacy of Mexiletine in Adolescents and Children With Myotonic Disorders
A regiszteradat frissítve
2024. november 25.